女股神Cathie Wood看好数码钱包及基因组学成颠覆性创新行业
女股神Cathie Wood向《CNBC》表示,数码钱包及基因组学是继Tesla及电动车後两个最大颠覆性趋势。
她称,对数码钱包的发展感到非常兴奋,认为可代替银行今日所扮演的不少角色。
Cathie Wood旗下ARKK基金在过去一年中获超过167亿美元资金流入,目前Wood已押注Square(SQ.US)及PayPal(PYPL.US)等股份,因这些公司在数码钱包市场上占据主导地位,当中Square是ARKK第二大持股,占比达7%以上。
另外她又提到,基因组学亦正以高速发展,基因排序首次将科学引入医疗决定当中,无需要再通过猜测或经验来作出医疗决定,认为这有助在未来能够治愈癌症等绝症。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.